Skip to content

NICE-CF: Colon Cancer Screening for adults with Cystic Fibrosis

Search Clinical Trials

Trial Objectives

Adults with cystic fibrosis (CF) are at a higher risk of developing colon cancer due to a mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.. Because of the increased risk, doctors recommend adults with CF begin receiving colon cancer screenings at age 40 or at age 30 if they are post-transplant. The purpose of the NICE-CF clinical trial is to compare the results of an at-home, stool-based test (e.g., a fecal immunochemical test AND Cologuard® test) to that of a colonoscopy, which is considered the best way to identify colon cancer. If the stool-based test is as reliable as a colonoscopy, researchers are hoping the convenience of an at-home test will encourage more adults with CF to get screened for colon cancer.

Participants will receive two at-home stool-based tests. Participants will be expected to complete a clinical colonoscopy as part of their routine standard of care.

Who Can Participate

Adults with CF ages 40-75 years old who have not had an organ transplant and are due for a colon cancer screening. Adults with CF ages 30-75 who have had an organ transplant and are due for a colon cancer screening.

Age: 30-75 Gender Any

Estimated Time Commitment

Three to 12 months, depending on the completion of the at-home test and the colonoscopy

Payment & Reimbursement

Payment Provided

Travel Reimbursement Not Available

Trial Contact

For more information, contact:

Salma Moreno

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Saint Louis University

Principal Investigators

Jeffrey B. King

Jeffrey B. King, MD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required